Key result
Desipramine therapy triggered neuroleptic malignant syndrome in a patient without neuroleptic exposure, suggesting the syndrome may be caused by a norepinephrine-dopamine imbalance.
Answers are grounded in this paper and cite their sources.
This case suggests that neuroleptic malignant syndrome may be caused by a central imbalance between norepinephrine and dopamine, rather than dopamine depletion alone.
We report the lst case of neuroleptic malignant syndrome occurring in a patient receiving desipramine, a tricyclic antidepressant, with no exposure to neuroleptics. Our case suggests that this syndrome may be caused by a central imbalance between norepinephrine and dopamine, and not by dopamine depletion alone.
No takes yet. Share an insight, caveat, or question.
Baca et al. (1990) studied this question. Desipramine therapy triggered neuroleptic malignant syndrome in a patient without neuroleptic exposure, suggesting the syndrome may be caused by a norepinephrine-dopamine imbalance.
Synapse has enriched 10 related papers. Consider them for comparative context: